



US009919050B2

(12) **United States Patent**
Dang et al.

(10) **Patent No.:** **US 9,919,050 B2**
(45) **Date of Patent:** ***Mar. 20, 2018**

(54) **COMPOSITIONS COMPRISING AZELASTINE**

(71) Applicant: **Meda Pharmaceuticals Inc.**, Somerset, NJ (US)

(72) Inventors: **Phuong Grace Dang**, Corona, CA (US); **Brian D. Lawrence**, Somerset, NJ (US); **Gul Balwani**, West Windsor, NJ (US); **Alexander D. D'Addio**, Piscataway, NJ (US)

(73) Assignee: **Meda Pharmaceuticals Inc.**, Somerset, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 247 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/974,881**

(22) Filed: **Aug. 23, 2013**

(65) **Prior Publication Data**

US 2014/0158117 A1 Jun. 12, 2014

Related U.S. Application Data

(60) Continuation of application No. 13/294,069, filed on Nov. 10, 2011, now Pat. No. 8,518,919, which is a division of application No. 11/284,109, filed on Nov. 22, 2005, now Pat. No. 8,071,073.

(60) Provisional application No. 60/630,274, filed on Nov. 24, 2004.

(51) **Int. Cl.**

A61K 47/26 (2006.01)

A61K 31/55 (2006.01)

A61K 9/00 (2006.01)

A61K 9/70 (2006.01)

A61K 45/06 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 47/26** (2013.01); **A61K 9/0043** (2013.01); **A61K 9/0048** (2013.01); **A61K 9/0056** (2013.01); **A61K 9/0073** (2013.01); **A61K 9/7007** (2013.01); **A61K 31/55** (2013.01); **A61K 45/06** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

158,564 A 1/1875 Barnes
2,119,643 A 6/1938 Mendl
2,136,940 A 11/1938 Ehbrecht
2,457,024 A 12/1948 Arp
2,822,314 A 2/1958 Ferlauto et al.
2,925,417 A 2/1960 Elslager et al.

2,995,308 A 8/1961 Ashkenaz
3,017,411 A 1/1962 Engelbrecht et al.
3,144,485 A 8/1964 Benn et al.
3,173,876 A 3/1965 Zobrist
3,267,586 A 8/1966 Molstedt et al.
3,541,005 A 11/1970 Strathmann et al.
3,541,006 A 11/1970 Bixler et al.
3,546,142 A 12/1970 Michaels et al.
3,753,988 A 8/1973 Rodway et al.
3,813,384 A 5/1974 Vogelsang et al.
3,845,052 A 10/1974 Stachel et al.
3,854,770 A 12/1974 Grise et al.
3,878,217 A 4/1975 Carr et al.
4,061,768 A 12/1977 Gorvin
4,077,407 A 3/1978 Theeuwes et al.
4,091,108 A 5/1978 Batchelor et al.
4,094,968 A 6/1978 Hodson et al.
4,226,848 A 10/1980 Nagai et al.
4,235,236 A 11/1980 Theeuwes
4,254,129 A 3/1981 Carr et al.
4,269,835 A 5/1981 Whittle
4,313,931 A 2/1982 Walther et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU 37674/72 7/1973
CA 2 455 939 A1 2/2003

(Continued)

OTHER PUBLICATIONS

Meltzer et al. in *Annals of Allergy* 72, 354-359 (1994).
La Force et al. in *Annals of Allergy, Asthma and Immunology* 76(2)181-188 (1996).
"Sweeteners" in <http://www.nutrientsreview.com/articles/sweeteners.html>. (retrieved from the internet Jan. 14, 2017).
Petition for *Inter Partes* Review of U.S. Pat. No. 8,071,073, in *Impax Laboratories, Inc.*, Petitioner v. *Meda Pharmaceuticals Inc.*, Patent Owner, Case IPR2014-00731, filed at the United States Patent and Trademark Office on May 7, 2014.
Assignment of U.S. Pat. No. 5,164,194 on Patent Application Information Retrieval, accessed at portal.uspto.gov/external/portal/pair, accessed on Apr. 22, 2014.

(Continued)

Primary Examiner — Dennis Heyer

(57) **ABSTRACT**

The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions, into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of allergic rhinitis, non-allergic vasomotor rhinitis, allergic conjunctivitis, as well as other disorders.

13 Claims, No Drawings